PAH-Related Morbidity as a Predictor of Mortality

2015 ESC/ERS Guidelines: Risk Assessment in PAH

A Multiparameter Risk Assessment Is Needed

ESC/ERS Guidelines: Assessment and Timing for Follow-Up of Patients With PAH

French Registry: BNP Subset Analysis

Prognostic Relevance of PAH-Related Morbidity

SERAPHIN and GRIPHON

Objective of the Landmark Analyses

Association Between Morbidity Before Month 3 and Mortality

Association Between Morbidity and Mortality at Any Landmark Time Point*

Morbidity Events in SERAPHIN and GRIPHON

GRIPHON: Association Between Individual Morbidity Components and Mortality

Importance of Thinking About the Future of Individual Patients Importance of Thinking About the Future of Individual Patients...NOT the Past

Looking Ahead…

Importance of Achieving Low-Risk Status at Follow-Up

Summary of 3 European Studies

Initial Treatment Approaches to PAH

Evolving Treatment Paradigm

Concluding Remarks

Abbreviations

Abbreviations (cont)